Drug intelligence / Profile preview

TMC-649128

Development stage: Discontinued
Lead developer: Medivir
Modality: Small Molecules
Administration: Oral

Overview

TMC-649128 is an investigational small molecule antiviral drug that was developed as an oral nucleoside inhibitor targeting the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. Its primary mechanism of action is inhibition of the HCV NS5B polymerase, thereby blocking viral replication. The drug was investigated for the treatment of chronic hepatitis C infection, specifically in genotype 1 HCV-infected patients. Clinical development reached Phase 1 trials but has since been discontinued. The original developers were Medivir AB and Tibotec Pharmaceuticals, with later involvement from Johnson & Johnson[1][3][5][7].

Other names: 4'-Azido-2'-deoxy-2'-methyl-cytidine di-isobutyryl ester

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on TMC-649128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMC-649128.

Explore the full profile